Prothena Corp Public (PRTA) Cash & Current Investments (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Cash & Current Investments came in at $329.5 million in Q1 2026, down 21.17% year-on-year from $417.9 million in Q1 2025, and up 7.13% quarter-over-quarter from $307.5 million in Q4 2025.
Prothena Corp Public (PRTA) Cash & Current Investments (2012 - 2026) Analysis & Trends
Prothena Corp Public's Cash & Current Investments history runs 15 years deep, the most recent figure standing at $329.5 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments fell 21.17% year-over-year to $329.5 million in Q1 2026; TTM through Mar 2026 was $329.5 million, a 21.17% decrease from a year earlier, with the FY2025 full-year figure at $307.5 million, down 34.76% from the prior year.
- Cash & Current Investments climbed to $329.5 million in Q1 2026 per PRTA's latest filing, from $307.5 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $710.4 million in Q4 2022 and bottomed at $307.5 million in Q4 2025.
- The 5-year median for Cash & Current Investments is $519.3 million (2024), against an average of $515.1 million.
- Across the five-year window, Cash & Current Investments surged 57.69% in 2022 and plunged 36.29% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $710.4 million in 2022, then decreased by 12.7% to $620.2 million in 2023, then decreased by 23.99% to $471.4 million in 2024, then sank by 34.76% to $307.5 million in 2025, then increased by 7.13% to $329.5 million in 2026.
- Per Business Quant, the three latest PRTA Cash & Current Investments figures stand at $329.5 million (Q1 2026), $307.5 million (Q4 2025), and $330.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Prothena Corp Public | 467.80 Mn | 138.33 Mn | - | 329.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 329.46 Mn |
| Dec 31, 2025 | 307.53 Mn |
| Sep 30, 2025 | 330.84 Mn |
| Jun 30, 2025 | 371.40 Mn |
| Mar 31, 2025 | 417.94 Mn |
| Dec 31, 2024 | 471.39 Mn |
| Sep 30, 2024 | 519.26 Mn |
| Jun 30, 2024 | 564.12 Mn |
| Mar 31, 2024 | 547.86 Mn |
| Dec 31, 2023 | 620.18 Mn |
| Sep 30, 2023 | 672.25 Mn |
| Jun 30, 2023 | 660.46 Mn |
| Mar 31, 2023 | 686.18 Mn |
| Dec 31, 2022 | 710.41 Mn |
| Sep 30, 2022 | 495.63 Mn |
| Jun 30, 2022 | 508.80 Mn |
| Mar 31, 2022 | 542.99 Mn |
| Dec 31, 2021 | 579.09 Mn |
| Sep 30, 2021 | 600.10 Mn |
| Jun 30, 2021 | 401.18 Mn |